“An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review”. 2024. Acta Medica Academica 53 (1): 46-58. https://doi.org/10.5644/ama2006-124.443.